EBITDA: Income before interest, taxes, depreciation and amortization.
Lexaria Bioscience Corp. (LEXX) had EBITDA of $-1.97M for the most recently reported fiscal quarter, ending 2026-05-31.
| Income Statement Financials | |
-- |
|
$-1.99M |
|
-- |
|
-- |
|
$1.99M |
|
$-1.99M |
|
$0.00M |
|
$-1.99M |
|
$-1.99M |
|
$-1.99M |
|
$-1.99M |
|
$-1.99M |
|
$-1.99M |
|
$-1.99M |
|
|
EBITDA |
$-1.97M |
1.65M |
|
1.65M |
|
$-1.20 |
|
$-1.20 |
|
| Balance Sheet Financials | |
$4.06M |
|
$0.23M |
|
$0.72M |
|
$4.78M |
|
$0.38M |
|
-- |
|
$0.05M |
|
$0.44M |
|
$4.34M |
|
$4.01M |
|
$4.34M |
|
1.65M |
|
| Cash Flow Statement Financials | |
$-4.78M |
|
$-0.09M |
|
$6.52M |
|
$1.80M |
|
$3.48M |
|
$1.67M |
|
$0.24M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.60 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.82M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-45.88% |
|
-49.76% |
|
-41.68% |
|
-45.88% |
|
$2.63 |
|
$-2.92 |
|
$-2.89 |
|